Micronized dHACM Injectable for the Treatment of Achille Tendonitis

May 18, 2022 updated by: MiMedx Group, Inc.

A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial Of The Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Achilles Tendonitis

Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis

Study Overview

Status

Completed

Conditions

Detailed Description

Approximately 158 subjects will be enrolled in this study. Each patient will receive 1 injection and be evaluated for efficacy and safety during a 12 month observation period. Randomization will be 1:1. The study is expected to be completed in 24 months, inclusive of enrollment and follow-up of all subjects.

Study Type

Interventional

Enrollment (Actual)

146

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35205
        • Central Research Associates
    • Arizona
      • Tucson, Arizona, United States, 85723
        • Southern Arizona VA Health Care System
    • California
      • Carlsbad, California, United States, 92009
        • ILD Research Center
      • Los Angeles, California, United States, 90057
        • Foot and Ankle Clinic
      • Pismo Beach, California, United States, 93449
        • Five Cities Foot Clinic
    • Florida
      • Miami, Florida, United States, 33125
        • South Florida Veterans Affairs
      • Miami, Florida, United States, 33143
        • Doctors Research Network
    • Georgia
      • Buford, Georgia, United States, 30518
        • Northside Podiatry
    • Illinois
      • Springfield, Illinois, United States, 62704
        • Foot and Ankle Center of Illinois
    • Nevada
      • Las Vegas, Nevada, United States, 89119
        • Advanced Foot & Ankle Center
    • Pennsylvania
      • Altoona, Pennsylvania, United States, 16602
        • University Orthopedics Center
      • Pittsburgh, Pennsylvania, United States, 15224
        • West Penn Hospital
    • Texas
      • McAllen, Texas, United States, 78501
        • Futuro Clinical Trials
    • Virginia
      • Virginia Beach, Virginia, United States, 23464
        • Coastal Podiatry, Inc.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

All subjects enrolled must meet all the following criteria:

  1. Confirmed diagnosis of Achilles tendonitis for ≥ 1 month (30 days) and ≤ 18 months by the investigator
  2. VAS Pain scale of ≥ 45 at randomization
  3. Achilles Tendonitis with conservative treatment for ≥1 month (30 days) while under the direction of the healthcare provider, including any of the following modalities:

    • Rest, Ice, Compression, Elevation (RICE)
    • Stretching exercises
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Orthotics
  4. Diagnostic AP and lateral X-Ray within 6 months of enrollment showing view of calcaneus negative for calcaneal fracture or structural abnormalities
  5. BMI ≤ 40 kg/m2
  6. Age from 21 to 80 years
  7. Ability to sign Informed Consent and Release of Medical Information Forms
  8. Ability to receive and respond to text messages or emails on a daily basis.

Exclusion Criteria Any potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent randomization.

  1. Prior surgery to the affected site.
  2. Subjects requiring bilateral Achilles tendonitis treatment at time of enrollment
  3. Prior use of any lower limb injection therapy, including corticosteroids or PRP in either limb within the last 3 months
  4. Has diabetes either Type I or Type II
  5. Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone attachments) such as Gout, Reiter's syndrome, rheumatoid arthritis, etc.
  6. The presence of diagnosed comorbidities that can be confused with or can exacerbate the condition- to be assessed by X-ray - including but not limited to:

    • Calcaneal stress fracture
    • Suspected partial thickness tear of the Achilles tendon, as assessed by the investigator
    • Calcaneal tumor
    • Tarsal tunnel syndrome (diagnosed)
    • Significant bone deformity of the foot that may interfere with the study
  7. The presence of diagnosed comorbidities that require surgery or are unlikely to improve - to be assessed by Investigator-including but not limited to:

    • Nerve entrapment syndrome
    • Acute traumatic rupture of the Achilles tendon
    • Partial thickness tears of the Achilles Tendon
  8. Affected site exhibits clinical signs and symptoms of infection
  9. Known allergy or known sensitivity to Aminoglycosides
  10. Subjects who are non-ambulatory
  11. History of more than 14 days of treatment with immune-suppressants (including systemic corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who are anticipated to require such medications during the course of the study
  12. Prior radiation at the site
  13. Use of any investigational drug(s) or therapeutic device(s) within 3 months preceding enrollment
  14. Immune system disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS), Human Immunodeficiency Virus (HIV) or Lyme disease
  15. History of any conditions (including drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol, in the judgment of the investigator
  16. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)
  17. Workers' compensation patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Saline Injection
Injection of 1mL 0.9% Sodium Chloride Injection, USP
Injection of 1mL 0.9% Sodium Chloride Injection, USP
Other Names:
  • Normal Saline
  • Sodium Chloride Injection, USP
  • 0.9% NaCL
EXPERIMENTAL: Micronized DHACM
1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)
1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
Other Names:
  • dHACM

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in VAS score
Time Frame: 90 days
Visual Analog Scale, Left end point is "No Pain". Right end point is "worst pain imaginable"
90 days
Incidence of adverse events
Time Frame: 365 days
The incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events during the first 12 months post injection
365 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Foot Function Index Revised (FFI-R) (Short Form)
Time Frame: 90 days
Subjects circle the number that correlates how bad their foot pain was in certain situation.
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stuart D Miller, MD, MedStar Union Memorial Hospital Baltimore, MD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 9, 2018

Primary Completion (ACTUAL)

March 30, 2021

Study Completion (ACTUAL)

March 30, 2021

Study Registration Dates

First Submitted

January 23, 2018

First Submitted That Met QC Criteria

January 26, 2018

First Posted (ACTUAL)

January 29, 2018

Study Record Updates

Last Update Posted (ACTUAL)

May 19, 2022

Last Update Submitted That Met QC Criteria

May 18, 2022

Last Verified

May 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • AIAT001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tendonitis;Achilles

Clinical Trials on Saline Injection

3
Subscribe